We are developing therapeutics designed to modulate the immune system, to overcome cancer immune tolerance and escape. We are also developing therapeutics designed to treat autoimmune diseases.
Amlitelimab SAR445229 (formerly KY1005), Alomfilimab SAR445256 (formerly KY1044) and KY1043 are designed to balance the activation and suppression of the immune system to treat disease.
We are building a rich pipeline of assets in four main therapeutic spaces: immune diseases, immuno-oncology, haematology and infectious diseases. Our most advanced assets entered development in 2017, and our first proof-of-concept clinical data is expected in 2020.Download Pipeline PDF
Our discovery platform enables us to develop therapeutic antibodies in immune diseases
We are using our unique expertise and technologies to develop innovative antibody-based molecular concepts in immuno-oncology
We are developing novel drug concepts in anaemia, haemophilia and other blood disorders